Ironwood Pharms Inc Drug Patent Portfolio
Ironwood Pharms Inc owns 2 orange book drugs protected by 9 US patents Given below is the list of Ironwood Pharms Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8546436 | Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof | 29 Feb, 2032 | Active |
| US9956205 | Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof | 28 Dec, 2031 | Active |
| US9216179 | Treatment of gout and hyperuricemia | 01 Aug, 2031 | Active |
| US8357713 | Compounds and compositions and methods of use | 22 Dec, 2029 | Active |
| US8084483 | Compounds and compositions and methods of use | 17 Aug, 2029 | Active |
| US8546437 | Compounds and compositions and methods of use | 29 Apr, 2029 | Active |
| US10183012 | Compounds and compositions and methods of use | 26 Nov, 2028 | Active |
| US8283369 | Compounds and compositions and methods of use | 26 Nov, 2028 | Active |
| US8003681 | 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and methyl ester | 25 Aug, 2025 | Active |
Latest Legal Activities on Ironwood Pharms Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Ironwood Pharms Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 10 Jul, 2024 | US8357713 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 27 Mar, 2024 | US8283369 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 14 Jun, 2023 | US8084483 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 07 Jun, 2023 | US9216179 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 08 Feb, 2023 | US8003681 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 06 Jul, 2022 | US10183012 |
|
Withdrawal of Application for PTE
Critical
| 21 Apr, 2022 | US8084483 |
|
Withdrawal of Application for PTE
Critical
| 21 Apr, 2022 | US8283369 |
|
Withdrawal of Application for PTE
Critical
| 21 Apr, 2022 | US8003681 |
|
Withdrawal of Application for PTE
Critical
| 21 Apr, 2022 | US8546437 |
|
Patent Term Extension Certificate
Critical
| 19 Apr, 2022 | US8357713 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Oct, 2021 | US9956205 |
|
Correspondence Address Change
Critical
| 01 Jun, 2021 | US10183012 |
|
Correspondence Address Change
Critical
| 27 May, 2021 | US8084483 |
|
Correspondence Address Change
Critical
| 27 May, 2021 | US8283369 |
Ironwood Pharms Inc Drug Patents' Oppositions Filed in EPO
Ironwood Pharms Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 14, 2017, by Stada Arzneimittel Ag. This opposition was filed on patent number EP11853861A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP11796324A | Dec, 2018 | Hexal AG | Revoked |
| EP11796324A | Dec, 2018 | Bülle Dr., Jan | Revoked |
| EP11796324A | Dec, 2018 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Revoked |
| EP11853861A | Sep, 2017 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Opposition rejected |
| EP11853861A | Sep, 2017 | STADA Arzneimittel AG | Opposition rejected |
Ironwood Pharms Inc's Family Patents
Ironwood Pharms Inc Drug List
Given below is the complete list of Ironwood Pharms Inc's drugs and the patents protecting them.
1. Duzallo
Duzallo is protected by 9 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8546436 | Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof |
29 Feb, 2032
(7 years from now)
| Active |
| US9956205 | Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof |
28 Dec, 2031
(7 years from now)
| Active |
| US9216179 | Treatment of gout and hyperuricemia |
01 Aug, 2031
(6 years from now)
| Active |
| US8357713 | Compounds and compositions and methods of use |
22 Dec, 2029
(5 years from now)
| Active |
| US8084483 | Compounds and compositions and methods of use |
17 Aug, 2029
(4 years from now)
| Active |
| US8546437 | Compounds and compositions and methods of use |
29 Apr, 2029
(4 years from now)
| Active |
| US10183012 | Compounds and compositions and methods of use |
26 Nov, 2028
(3 years from now)
| Active |
| US8283369 | Compounds and compositions and methods of use |
26 Nov, 2028
(3 years from now)
| Active |
| US8003681 | 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and methyl ester |
25 Aug, 2025
(8 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Duzallo's drug page
2. Zurampic
Zurampic is protected by 9 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8546436 | Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof |
29 Feb, 2032
(7 years from now)
| Active |
| US9956205 | Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof |
28 Dec, 2031
(7 years from now)
| Active |
| US9216179 | Treatment of gout and hyperuricemia |
01 Aug, 2031
(6 years from now)
| Active |
| US8357713 | Compounds and compositions and methods of use |
22 Dec, 2029
(5 years from now)
| Active |
| US8084483 | Compounds and compositions and methods of use |
17 Aug, 2029
(4 years from now)
| Active |
| US8546437 | Compounds and compositions and methods of use |
29 Apr, 2029
(4 years from now)
| Active |
| US10183012 | Compounds and compositions and methods of use |
26 Nov, 2028
(3 years from now)
| Active |
| US8283369 | Compounds and compositions and methods of use |
26 Nov, 2028
(3 years from now)
| Active |
| US8003681 | 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and methyl ester |
25 Aug, 2025
(8 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zurampic's drug page